Table 4 The effect of the ASM regimen on DRE status among PWE
From: Drug-resistant epilepsy in Saudi Arabia: prevalence, predictive factors, and treatment outcomes
ASM | Regimen | DRE (%) | AOR (95% CI) | p-Value | |
|---|---|---|---|---|---|
No | Yes | ||||
Levetiracetam (N = 164) | Monotherapy (N = 105) Polytherapy (N = 59 ) | 86 (81.9) 45 (76.2) | 19 (18.0) 14 (23.7) | 0.71 (0.33,1.55) | 0.51 |
Carbamazepine (N = 93) | Monotherapy (N = 62) Polytherapy (N = 31) | 54 (87.0) 19 (61.2) | 8 (12.9) 12 (38.7) | 0.23 (0.08,0.066) | 0.0097* |
Valproic acid (N = 49) | Monotherapy (N = 32) Polytherapy (N = 17 ) | 30 (93.7) 8 (47.0) | 2 (6.2) 9 (52.9) | 0.059 (001.033) | 0.0008* |
Lamotrigine (N = 37) | Monotherapy (N = 23) Polytherapy (N = 14) | 16 (69.5) 4 (28.5) | 7 (30.4) 10 (71.4) | 0.17 (0.04,0.75) | 0.037* |
Phenobarbital (N = 16) | Monotherapy (N = 5) Polytherapy (N = 11) | 4 (80.0) 8 (72.7) | 1 (20.0) 3 (27.2) | 0.66 (0.05,8.64) | 1.00 |
Phenytoin (N = 12) | Monotherapy (N = 7) Polytherapy (N = 5) | 6 (85.7) 4(80.0) | 1(14.2) 1(20.0) | 0.66 (0.03, 14.04) | 1.00 |
Topiramate (N = 7) | Monotherapy (N = 2) Polytherapy (N = 6) | 1(50.0) 4 (66.6) | 1(50.0) 2 (33.3) | 2.0 (0.08,51.60) | 1.00 |
Lacosamide (N = 4) | Monotherapy (N = 3) Polytherapy (N = 1) | 3(100) 0 | 0 1(100) | NA | 0.50 |
Others (N = 11) | Monotherapy (N = 6) Polytherapy (N = 5) | 6(100) 2(40.0) | 0 3(60.0) | NA | 0.12 |